Publicacións nas que colabora con Isabel Illa Sendra (24)

2023

  1. Erratum: New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy(Brain (2020) 143:9 (2696–2708) DOI:10.1093/brain/awaa228)

    Brain

2022

  1. Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome

    Annals of Clinical and Translational Neurology, Vol. 9, Núm. 2, pp. 122-131

  2. Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values

    Clinical Neurophysiology, Vol. 138, pp. 231-240

  3. International Validation of the Erasmus Guillain–Barré Syndrome Respiratory Insufficiency Score

    Annals of Neurology, Vol. 91, Núm. 4, pp. 521-531

  4. Predicting Outcome in Guillain-Barré Syndrome International Validation of the Modified Erasmus GBS Outcome Score

    Neurology, Vol. 98, Núm. 5, pp. E518-E532

2021

  1. Clinical characteristics and outcomes of thymoma-associated myasthenia gravis

    European Journal of Neurology, Vol. 28, Núm. 6, pp. 2083-2091

2020

  1. COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)

    The Lancet Neurology

  2. New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy

    Brain, Vol. 143, Núm. 9, pp. 2696-2708

2019

  1. Current treatment practice of Guillain-Barré syndrome

    Neurology, Vol. 93, Núm. 1, pp. E59-E76

  2. Muscle MRI in a large cohort of patients with oculopharyngeal muscular dystrophy

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 90, Núm. 5, pp. 576-585

  3. PDGF-BB serum levels are decreased in adult onset Pompe patients

    Scientific Reports, Vol. 9, Núm. 1

  4. Study of the effect of anti-rhGAA antibodies at low and intermediate titers in late onset Pompe patients treated with ERT

    Molecular Genetics and Metabolism, Vol. 128, Núm. 1-2, pp. 129-136

2018

  1. Quantitative muscle MRI to follow up late onset Pompe patients: A prospective study

    Scientific Reports, Vol. 8, Núm. 1

  2. Regional variation of Guillain-Barré syndrome

    Brain, Vol. 141, Núm. 10, pp. 2866-2877

  3. The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis

    Annals of Clinical and Translational Neurology, Vol. 5, Núm. 6, pp. 710-716

2017

  1. Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15

    Journal of Neuroinflammation, Vol. 14, Núm. 1

  2. Distribution and genotype-phenotype correlation of GDAP1 mutations in Spain

    Scientific Reports, Vol. 7, Núm. 1

  3. International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome

    Journal of the Peripheral Nervous System, Vol. 22, Núm. 2, pp. 68-76

2015

  1. Myasthenia gravis: Descriptive analysis of life-threatening events in a recent nationwide registry

    European Journal of Neurology, Vol. 22, Núm. 7, pp. 1056-1061

  2. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins

    Neurology: Neuroimmunology and NeuroInflammation, Vol. 2, Núm. 5, pp. e149